A Phase I clinical trial evaluated the safety and tolerability of intravenous mistletoe extract in patients with advanced solid tumors. Mistletoe extract has been used as a complementary therapy in cancer treatment, and this study aimed to determine the maximum tolerated dose and any adverse effects of the treatment.The trial enrolled 24 patients, and the mistletoe extract was administered intravenously once a week for three weeks, followed by a one-week break. The study found that mistletoe extract was well-tolerated, and there were no dose-limiting toxicities observed. The most common adverse events were mild and included fatigue, fever, and nausea.The researchers also observed some preliminary evidence of anti-tumor activity, with one patient experiencing a partial response and several patients experiencing stable disease.Overall, the study suggests that intravenous mistletoe extract is safe and well-tolerated in patients with advanced solid tumors.
